Diabetes

Filling in the Blanks: The Patient-Provider Conversation About Biosimilars

February 22nd 2021

By Tony Hagen

Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.

Study: Gender, Internet Habits Influence Biosimilar Acceptance

February 15th 2021

By Tony Hagen

Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.

Biocon Gains EU Authorization for Insulin Aspart Biosimilar

February 12th 2021

The Bengaluru, India, company said the fast-acting biosimilar will improve affordability of insulin in Europe, which also faces rising prices and access problems.

Lannett, HEC Pharm Team Up on Insulin Aspart Biosimilar Project

February 11th 2021

By Tony Hagen

Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.

Nurses Can Counter Nocebo Effect in Biosimilar Switching

January 27th 2021

By Tony Hagen

The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24th 2020

By Tony Hagen

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Biocon/Mylan Receive CHMP Nod for Insulin Aspart Biosimilar in European Union

December 14th 2020

By Tony Hagen

The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected to be followed by a European Commission final decision early in 2021.

Newly Created Viatris Joins the Biosimilars Forum

November 30th 2020

By Tony Hagen

The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.

IGBA Launches Global Biosimilars Week

November 16th 2020

By Tony Hagen

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

November 2nd 2020

By Deana Ferreri, PhD

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.